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Abstract
This manuscript is composed of five parts which summarize five publications in succession. Essentially,
they are concerned with molecular diagnostics of Lynch syndrome and are based on studies in 238 families.
The finding that young age at diagnosis is the key feature in patients with MSH2 and MLH1 mutations
(Part 1) has helped to define simple criteria for the preliminary diagnosis of this syndrome. A cheaper
method for the detection of mutations has been developed (Part 2) and applied to study the types of
mutations and their prevalence in Poland (Part 3) and the Baltic States (Part 4). A specific feature of these
mutations, i.e. presence of recurrent mutations in the majority of affected families with mutations, has
suggested the feasibility of effective diagnostics with a single test disclosing all of them. An attempt to
reveal other causes of familial aggregation of colorectal cancer has ruled out any association with C
insertion in the NOD2 gene (Part 5).
Introduction
More than 90 years ago, Warthin described 
a family in which members from several generations
died at a young age because of colorectal cancer
(CRC) or carcinoma of the endometrium [1]. The
clinical characteristics of this disorder, called hereditary
non-polyposis colorectal cancer (HNPCC) or Lynch
syndrome, which was the reason for the early dead
cases in that family, were shown many years later by
Lynch [2]. The members of families with Lynch
syndrome are particularly at risk of developing cancers
of the colon and endometrium inherited as monogenic
disorders with high penetration in an autosomal
dominant manner. Today it is well known that this
disorder results from a mutation carrier state in one
of the mutator genes and can be defined as hereditary
deficiency of mismatch repair (MMR) activity. There
are at least four genes definitely associated with
HNPCC, and these include MLH1 [3], MSH2 [4],
MSH6 [5] and PMS2 [6]. Two further genes, MLH3 and
PMS1, have also been implicated in HNPCC, but their
role is less clear [7-9]. The majority of mutations lead
to truncation of the encoded protein (based on the
Insight database – http://www.insight-group.org/).
Usually, pathogenicity of mutations is caused by the
loss of an important protein domain or a change of
structure in the site of interaction with other mismatch
repair proteins. Deficiency of MMR activity manifested
as microsatellite instability (MSI) and loss of expression
of mutated genes in cancer has been used as a pre-
selective factor in many diagnostic procedures, also
investigated by the author [10, 11]*.
At first, diagnosis of this syndrome was based mainly
on the Amsterdam criteria (Table 1), which were
proposed by the International Collaborative Group on
HNPCC – ICG-HNPCC [12]. 
Afterwards, these criteria were expanded [13] by
adding cancers characteristic for HNPCC tumours
such as: endometrium, small intestine, urinary tract
(HNCCP related cancer – HNPCC-rc). Despite all the
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Table 1. Diagnostic criteria of HNPCC according to ICG-HNPCC
Amsterdam criteria I Amsterdam criteria II
Colorectal cancer confirmed histologically in at least three Cancer1 confirmed histologically in at least three affected relatives,
affected relatives, one of whom is a first-degree relative one of whom is a first-degree relative of the other two
of the other two
At least two first-degree relatives in two successive generations At least two first-degree relatives in two successive generations
At least one member diagnosed with colorectal cancer At least one member diagnosed with cancer1 before age 50 years
before age 50 years
Familial adenomatous polyposis has been excluded Familial adenomatous polyposis has been excluded
1colorectal or endometrial or small intestine or urinary tract cancer (HNPCC-related cancers).
modifications, it appears that their sensitivity was not
adequate. In a population tested by Syngal et al. [14],
39% of families with MSH2 and MLH1 mutations did
not fulfil the Amsterdam criteria. Better criteria,
concerning sensitivity, were the Bethesda criteria [15],
which were not sufficiently specific. The criticism of the
Amsterdam criteria led to the definition of other
criteria, which could not be as specific as previous,
but which have greater application in practical
diagnosis. These criteria, acknowledged by an
international group of specialists from ICG-HNPCC,
were in year 2000 the Parks criteria (developed by
using information about families with mutations
detected in the Pomeranian Academy of Medicine in
Szczecin) [16]*, which were modified later [17]*. 
Analysis of information from the literature, related
to correlation between occurrence of constitutional
mutations in the MSH2 and MLH1 genes, and the
clinical and pedigree features, allowed the
hypothesis to be made that in families with CRC
aggregation unclassified to the Amsterdam criteria
prevalence of MSH2 and MLH1 gene mutations is
very high and sequencing without any pre-selection
can be applied if cancers are diagnosed at early
age [14, 18-22]. 
PART 1
Age at diagnosis of colorectal cancer as a predictor 
of mutations of MSH2 and MLH1 genes 
in families suspected of HNPCC
(Based on publication no. 1: Age at diagnosis of cancer as predictor 
of mutation occurrence in families suspected of HNPCC [23]*)
Analysis of significance of age at cancer diagnosis
as a factor allowing identification of a subgroup of
patients with a high frequency of MSH2 and MSH1
mutations among families that fulfil suspected HNPCC
criteria was performed. In this study frequency of
mutation of MSH2 and MLH1 was compared between
groups of patients matching the Park I criteria and
discriminated by the age of diagnosis. DNA from thirty-
one unrelated patients affected by colorectal cancer from
families matching the above criteria [16]* (Table 2) was
studied by direct sequencing for occurrence of MSH2
and MSH1 gene mutations. 
Seven mutations were detected: five in the MLH1
gene and two in the MSH2 gene. All seven mutations
were found in a subgroup of 19 patients with cancer
diagnosed before the age of 50 years. In a subgroup
Table 2. Park I criteria for suspected HNPCC families (according to [16]*). At least one item in each category must be met (A or B) and (C
or D or E)
Category I Category II
A – vertical transmission of colorectal cancer C – multiple colorectal tumours (including polyps)
B – at least two siblings affected with colorectal cancer in a family D – at least one colorectal cancer diagnosed before the age of 50 years
– E – development of extracolonic cancer (endometrium, small intestine, 
urinary tract, stomach, hepatobiliary system or ovary) 
in family members
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of 12 patients with cancer diagnosed at an older age
only one case of MLH1 alteration of unknown
significance was detected. Our results indicate that
early age at cancer diagnosis seems to be a crucial
pedigree factor in discrimination of patients with MSH2
or MLH1 mutations among families suspected of
HNPCC and matching Park’s criteria I.
The meaning of criteria of age at diagnosis and
presence of at least two cancers diagnosed in first-degree
relatives in kindreds was verified on greater genetic
material, with cooperation of the Pomeranian Academy
of Medicine in Szczecin with German and Danish
scientists, entitled: Nuclear Pedigree Criteria of Suspected
HNPCC [24]*. That canon has become the main
standard, used in daily work with patients suspected of
HNPCC. The criteria are summarized in Table 3. 
Analysis of families with HNPCC based only on
pedigree and clinical criteria is insufficient, because it
did not allow definite identification of patients
suspected of HNPCC, or eliminate from the group at
risk patients without any mutations. Currently, clinical
and pedigree criteria are used to pre-select patients
diagnosed by molecular diagnostics.
PART 2
Molecular techniques for the detection of mutations 
– mutation analysis of MSH2 and MLH1 genes using DHPLC
(Based on publication no. 2: Mutation analysis of MLH1 and MSH2 genes
performed by denaturing high-performance liquid chromatography [25]*)
The most sensitive mutation detection technique is
considered to be direct sequencing. The first mutations
in Polish families with HNPCC [26, 27]* were detected
by the mentioned technique in the Pomeranian Academy
of Medicine, Szczecin, Poland. However, sequencing of
MLH1 and MSH2 genes is technically demanding, time-
consuming and expensive for Polish economic conditions.
Reduction of costs was possible by using a cheaper
screening method to detect changes in DNA and reduce
DNA sequencing only to confirm this. The Pomeranian
Academy of Medicine in Szczecin initially tried to obtain
some savings using single-strand conformation
polymorphism (SSCP). Unfortunately these techniques
were not sensitive enough to detect mutations as well as
direct sequencing. Also the trial of reduction of cost by
sequencing cDNA obtained by reverse transcription of
DNA to detect mutations [28]* turned out not to be
sufficiently helpful in practice. The main reason for that
was the difficulty in organization to achieve suitable quality
of material to isolate RNA. 
Studies show very high sensitivity of denaturing
high-performance liquid chromatography (DHPLC) in
detection of mutations of different genes [29], which
leads us in the current paper to make an attempt to
develop an economical version of this method, in
relation to MLH1 and MSH2 – the main genes
connected with HNPCC. It was based on establishing
of optimal terms of chromatographic development: the
temperature and gradient profile for 36 amplicons of
MLH1 and MSH2 genes. We investigated the sensitivity
and specificity of DHPLC analysis for the detection of
mutations. For the studies we took 46 patients with
CRC from families with HNPCC. 19 patients had
previously been identified by DNA sequencing. In 27
patients (who had not previously been tested) 16 rare
changes were detected, including 4 mutations not
described earlier in other populations. Generally, we
did not observe false positive or false negative results.
Elution profiles were highly characteristic for a given
change and in 98.5% of cases allowed the distinction
between novel alterations and previously identified
mutations and polymorphisms. For the detection of
changes in almost all amplicons, it was sufficient to
use just one denaturing temperature. Results of this
study support that DHPLC is a highly sensitive, specific
and cost-effective technique with a particularly high
potential for diagnostic laboratories involved in the
identification of MSH2 and MLH1 gene mutations. 
PART 3
Types and prevalence of MSH2 and MLH1 mutations 
in HNPCC families from Poland
(Based on publication no. 3: Germline MSH2 and MLH1 mutational
spectrum including large rearrangements in HNPCC families from Poland
(update study) [30]*)
Currently, 448 different mutations from different
populations have been reported in these genes as
Table 3. Modified criteria for suspected HNPCC families
I – at least one HNPCC cancer (colorectal, endometrial, small intestine, urinary tract) has been diagnosed in first-degree relatives 
of patient with colorectal cancer
II – at least one of them was diagnosed before the age of 50 years
III – FAP has been excluded
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described in the Insight Group Database. MLH1 and
MLH2 genes show abnormalities in almost 90% of
HNPCC families with identified germline mutations.
The majority of reported MLH1 and MSH2 mutations
are dispersed throughout the 35 exons of these two
genes. The majority of mutations are frameshift or
nonsense mutations that lead to truncated proteins.
Recently it has been suggested that genomic deletions
of one or more exons account for a significant
percentage of the MSH2 and MLH1 mutations 
[32-38]. Many of the MSH2 and MLH1 changes
including large deletions are recurrent and are
described as founder mutations in particular populations
[33, 35-44]. To develop efficient DNA-testing protocols,
it is important to describe the nature and frequency
of mutations in different ethnic groups. Herein, we
describe the results of analyses of detecting MSH2
and MLH1 gene mutations in a series of 226 HNPCC
families from all regions of Poland (among all
publications of that kind, this is the biggest in Eastern
Europe and one of the biggest in the whole world)
DNA was extracted directly from blood
leukocytes. To confirm some mutations, RNA-sequen-
cing and tissues from paraffin block were also used.
RNA-sequencing template was used for patients with
deletions detected by the MLPA assay of genomic
DNA. Some of the mutations were confirmed by
immunohistochemical staining of tumour tissues. For
the studies we took unrelated patients from families
matching the Amsterdam II criteria or at least our
modified criteria (Table 3). Patients used for this study
were ascertained from the following regions:
Bia³ystok – 2, Bydgoszcz – 9, Bytom – 2, Gdañsk
– 10, Gliwice – 1, Gorzów – 3, Jelenia Góra – 1,
Kielce – 18, Koszalin – 4, Kraków – 7, Legnica – 4,
Lublin – 4, £ódŸ – 3, Olsztyn – 27, Opole – 6,
Poznañ – 13, Rzeszów – 2, Szczecin – 71, Œwidnica
– 7, Œwinoujœcie – 1, Warszawa – 3, Wroc³aw – 16
and Zielona Góra – 12. 
This study was approved by the Institutional Human
Ethics Review committee of the Pomeranian Medical
University. 
Among 78 families, 50 different pathogenic mutations
were found, 25 in MSH2 and 25 in MLH1 (Table 4).
Twenty-four mutations have not been described earlier
in other populations. Among 78 families with MLH1 and
MSH2 mutations, 54 (69.2%) were affected by recurrent
mutations including 38 found at least twice in our own
series. Two of the most frequent alterations were a
substitution of A to T at the splice donor site of intron 5
of MSH2, which is the most common mutation in the
world connected with HNPCC [45], and a missense
change (A681T) of MLH1 found in 10 and 8 families,
respectively.
Using MLPA analyses revealed 7 patients with 6
different deletions. This equates to almost 10% of
probands with identifiable MSH2 and MLH1 mutations.
Five different deletions were detected in MSH2. Two of
these showed loss of single exon 9, which is located
between two large introns. 
Our results indicate that a screening protocol that is
limited to the detection of all reported mutations will result
in the identification of the majority of changes present in
MLH1 and MSH2 genes in Polish HNPCC kindreds. 
PART 4
Types and prevalence of MSH2 and MLH1 mutations 
in HNPCC families from the Baltic States
(Based on publication no. 4: Germline MSH2 and MLH1 mutational
spectrum in HNPCC families from Poland and the Baltic States [46]*)
Genetic disease shows population distinctiveness
at a molecular and clinical level. However, some
changes are recurrent and are described as founder
mutations in particular populations. To develop
efficient DNA testing, it is important to describe the
nature and frequency of mutations that are
characteristic of particular ethnic groups. The MSH2
and MLH1 mutation spectrum has been investigated
in the Eastern Europe region by the author in a paper
from 2002 [46]*. We screened 101 HNPCC kindreds
fulfilling the Amsterdam II diagnostic criteria or our
suspected HNPCC criteria (Table 3). The results
concerning 89 Polish families were described in Part
3 of the current paper. Also there were 12 families
tested, 6 from Lithuania, 3 from Latvia and 3 from
Estonia. Among patients from the Baltic States, there
were found two mutations and one change suspected
of pathogenic character. Two of the most frequent
mutations identified in Poland were also found in
Lithuanian families, suggesting a common history.
Poland and the Baltic States may have more common
mutations than reported here since the number of
samples from Estonia, Latvia and Lithuania were too
small to make the appropriate comparisons.
In summary, it seems likely that the MSH2 and
MLH1 changes described here are representative of
the majority of HNPCC mutations in families from
this region. Therefore, we believe it is justified to
develop a DNA testing strategy based on the
preferential analysis of changes identified from this
population.
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Table 4. Germline MSH2 and MLH1 mutations in Polish HNPCC families
Mut. Gene/exon Position of nucleotide Consequence Number Reported in other
No. or intron with mutation of families populations
1. MSH2/1 c.4 G>A A2T 1 yes
2. MSH2/1–6 unknown del ex1–6 in DNA1 1 ?
3. MSH2/2 del/ins2 Premature nonsense codon 1 no
4. MSH2/3–6 unknown del ex3–6 in DNA 1 ?
5. MSH2/3 c.435T>G I45M 1 yes
6. MSH2/3 c.613G>T E205X 1 no
7. MSH2/SD3 c.645 + 1g>t del ex3 no reading frame shift 1 no
8. MSH2/4 c.715 C>T Q239X 1 no
9. MSH2/SD5 c.942 + 3a>t del ex5 no reading frame shift 10 yes
10. MSH2/7 c.1204C>T Q402X 1 no
11. MSH2/7 c.1215C>A Y405X 1 no
12. MSH2/7 c.1216C>T R406X 2 yes
13. MSH2/7–16 unknown del ex7–16 in DNA3 1 ?
14. MSH2/8 unknown del ex8 in DNA4 1 ?
15. MSH2/9 unknown del ex in DNA4 2 ?
16. MSH2/SD10 c.1661 + 5g>c del ex10 with reading frame shift 1 no
17. MSH2/11 c.1705–1706delGA reading frame shift 1 no
18. MSH2/12 c.1771–1772insA reading frame shift 1 no
19. MSH2/12 c.1968C>G R656X 1 yes
20. MSH2/13 c.2131C>T R711X 1 yes
21. MSH2/SD13 c.2210 + 1g>c del ex13 with reading frame shift 1 no
22. MSH2/14 c.2305delT reading frame shift 1 no
23. MSH2/14 c.2388delT reading frame shift 1 no
24. MSH2/14 c.2422G>T E808X 2 no
25. MSH2/SD15 c.2634 + 1g>a del ex15 with reading frame shift 1 yes
26. MLH1/1 c.37delG reading frame shift 1 no
27. MLH1/1 c.66delG reading frame shift 1 yes
28. MLH1/1 c.83C>T P28L 3 yes
29. MLH1/2 c.161delG reading frame shift 1 no
30. MLH1/2 c.184C>T Q62X 2 yes
31. MLH1/2 c.199G>A G67R 1 yes
32. MLH1/3 c.256C>T Q86X 1 no
33. MLH1/4 c.350C>T T117M 1 yes
34. MLH1/4 c.356–357insAA reading frame shift 1 no
35. MLH1/5 c.392C>A S131X 1 no
36. MLH1/7SA c.546–2a>g del ex7 with reading frame shift 1 yes
37. MLH1/SD8 c.677G>T del ex8 with reading frame shift 3 yes
38. MLH1/10 g.37019613–37020677del1064 del ex10 in DNA4 1 no
39. MLH1/SD10 c.883delAGgt del ex10 with reading frame shift 1 no
40. MLH1/SD10 c.883A>C (c.884-2A>C) del ex10 with reading frame shift 1 no
41. MLH1/12 c.1252–1253delGA reading frame shift 1 no
42. MLH1/12 c.1321G>A A441T 3 yes
43. MLH1/SD12 c.1409 + 1g>c del ex12 with reading frame shift 1 yes
44. MLH1/13 c.1489–1490insC reading frame shift 3 yes
45. MLH1/15 c.1672G>T E558X 1 yes
46. MLH1/15 c.1731G>A del ex15 with reading frame shift 1 yes
47. MLH1/16 c.1852–1854delAAG 618delK 1 yes
48. MLH1/18 c.2040C>A C680X 1 no
49. MLH1/18 c.2041G>A A681T 8 yes
50. MLH1/19 c.2223delGCAGCTTGCTA reading frame shift 1 no
? – definite answer is difficult without breakpoint sequencing 
mutations not found previously in other populations shown in bold; 




AATCCCACTTTACTTAAAACTCACAG (premature nonsense codon in bold); 3 shorter transcript of allele with deletion; 4 exon deleted and reading frame shift.
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PART 5
Mutations of genes unrelated to MMR as a possible
aetiological factor in Lynch syndrome
(Based on publication no. 5: The NOD2 3020insC mutation and the risk
of colorectal cancer [47]*)
Lynch syndrome generally results from a mutation
carrier state in MSH2 or MLH1 genes. Occasionally,
similar clinical and pedigree characteristics may be
due to mutations in a variety of other genes, including
APC [48], TGFbRII [49], CDH1 [50], EXO1 [51] and
MYH [52]. With rare exceptions (EXOI), tumours from
such families do not display MSI. Since mutations in
the NOD2 gene were associated with Crohn’s disease
(CD) and a risk of colorectal cancer was suggested to
be increased in this disorder [53], the author has made
an attempt to answer the question whether the carrier
state of insertion C could imitate clinical-pedigree
characteristics of HNPCC.
The NOD2 gene comprises 12 exons and encodes
a protein of 1040 amino acids [54]. The predicted motifs
encoded by the NOD2 gene suggest that it is involved
in the dysregulation of immune function by either
affecting a change in the detection or binding of
bacterial proteins and/or impaired nuclear factor – kB
[55] signalling. Recently, three common variants have
been identified that have been associated with an
increased likelihood of CD, two of which are missense
changes, and one an insertion mutation. The insertion
mutation 3020insC has been shown, when inherited in
the homozygous state, to be associated with an almost
20-fold risk of developing CD, whereas if present in the
heterozygous state, it increases risk by ~3-fold [56]. 
The following groups of patients were taken for the
studies:
• 156 patients with CRC matching the AMS II criteria
or criteria of suspected HNPCC used in our centre
but without MSH2 or MLH1 constitutional mutations; 
• 250 consecutive patients with CRC diagnosed after
50 years of age from families without any clinical
and pedigree features, leading to diagnosis of
HNPCC definitely or with high probability;
• 50 consecutive patients with CRC diagnosed before
50 years of age from families without any clinical
and pedigree features, leading to diagnosis of
HNPCC definitely or with high probability;
• 100 CRC patients from the genetic counselling unit
(of the International Hereditary Cancer Centre in
Szczecin) from families where there were at least two
other malignancies diagnosed on the same side of
the family that confirmed an undefined cancer family
aggregation;
• 300 consecutive newborns from the clinical hospitals
of Szczecin. 
DNA samples were obtained from the peripheral
blood of CRC patients or from umbilical cord blood of
newborns. The method described by Ogura [54] was
used to identify the 3020insC alteration. The sequences
of the PCR products were confirmed by DNA sequencing. 
There was no association between carrier-state of
3020insC and prevalence aggregation of malignant
adenoma (HNPCC and CFA) and with predisposition to
CRC before 50 years of age. In contrast, frequency of that
variant was considerably higher in the group of patients
with CRC (n=250) diagnosed over 50 years of age than
in the group of newborns (OR=2.23; p=0.0046).
The results of the study show that DNA tests detecting
the 3020insC mutation can be used to detect increased
predisposition to CRC in a group of patients diagnosed
after 50 years of age, who came from families without
pedigree and clinical characteristics, allowing unequivocal
identification of diseases or high probability of it. 
Summarization of results 
1. Constitutional mutations of MSH2 and MLH1 genes
occur more frequently in families with suspected
Lynch Syndrome, in which at least one member of
the family is diagnosed under the age of 50 years.
2. Denaturing high-performance liquid chromatography
shows sensitivity and specificity comparable to
sequencing in detection of constitutional changes in
MLH1 and MSH2 genes. 
3. Characteristic features of the constitutional mutations
detected in MLH1 and MSH2 genes in 78 Polish
families with Lynch syndrome are the following: 
a) Types and frequencies of changes are characteristic
for the Polish population; around 50% of them (24
of 50) has been described for the first time; 
b) The recurrent mutations account for a high percentage
– 69.2%, of all mutations; the two most frequent of
them are c.943+3a>t in MSH2 and c.2041G>A in
MLH1;
c) Mutations detected by sequencing or DHPLC
account for 91% (71 of 78), and mutations detected
by MLPA test (large deletions) account for 9% (7 of
78) of all mutations. 
4. Mutations in MSH2 and MLH1 genes identified in
Poland have been found also in Lithuania.
5. The frequency of NOD2 3020insC gene variant in
families with HNPCC without mutation in MLH1 and
MSH2 genes, was not increased. The 3020insC variant
in CRC patients diagnosed above the age of 50 was
found twice as frequently as in control group.
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Conclusions 
1. Effective molecular diagnostics based on detection of
the constitutional mutations in MSH2 and MLH1
genes is not only possible in families matching the
Amsterdam II criteria, but also in HNPCC suspected
families, in which at least one member of the family
was diagnosed with cancer under the age of 50 years. 
2. Application of the DHPLC method for detecting MSH2
and MLH1 gene mutations and the use of sequencing
for only to confirmation and characterization of
changes, contributes to substantial reduction of costs
(about 10x) of molecular diagnostics in Lynch
syndrome.
3. The results show that DNA screening tests, limited
to detection of all mutations described in the present
paper, allow identification of the majority of
mutations present in MSH2 and MLH1 genes in
Polish families with HNPCC.
4. DNA tests for detecting MSH2 and MLH1 gene
mutations in Eastern Europe will probably be based
on mutations identified for the first time in Poland.
5. DNA tests for detection of 3020insC in the NOD2
gene can be used to identify the increased risk of
CRC, among patients above 50 years of age from
families without any clinical and pedigree features of
HNPCC diagnosed definitely or with high probability.
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